(CercleFinance.com) – AlphaValue renewed its buy recommendation on Sanofi on Wednesday, with a target price of 132 euros corresponding to an upside potential of 38%.
At a time when other securities in the sector such as Novo Nordisk or Eli Lilly are focusing the attention of investors, the research office believes that it is also time to look into the French pharmaceutical giant, of which it praises the ‘silent performance ‘.
Over the past five years, Sanofi has seen its profitability as its stock market valuation progress at a steady pace, despite the difficulties the laboratory has had to face, he points out.
Regarding its prospects, not only does its star drug Dupixent still show significant growth potential, but the group also has promising projects in other areas, notes AlphaValue.
With a current PER of 15x compared to a historical average of 20x over the period 2013-2022, the stock is now showing a discounted valuation which makes the research firm say that the stock represents an attractive investment opportunity.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
